title: Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.
abstract: Aflibercept is a fully human, recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members, including VEGF-A, VEGF-B and placental growth factor (P1GF), thereby inhibiting downstream signalling mediated by these ligands. Aflibercept binds all isoforms of VEGF-A with high affinity, and a markedly higher affinity than that of ranibizumab or bevacizumab. A formulation of aflibercept developed specifically for intravitreal injection (Eylea(®)) is approved for use in several countries for the treatment of patients with macular oedema secondary to central retinal vein occlusion (CRVO). In clinical trials (GALILEO and COPERNICUS) in patients with this condition, intravitreal aflibercept 2 mg every month improved best corrected visual acuity (BCVA), as measured by the proportion of study eyes with a gain of ≥15 Early Treatment Diabetic Retinopathy Study letters from baseline, significantly more than sham injections at week 24 (primary analysis). The significant improvements achieved with intravitreal aflibercept compared with sham in the first 6 months were maintained in the second 6 months with as-needed (prn) dosing and monthly monitoring. Continued prn dosing with a reduced monitoring frequency was associated with decreased improvements. More data are needed to confirm the optimal monitoring frequency for use with prn dosing, subsequent to initial monthly injections, in order to maintain long-term efficacy. Intravitreal aflibercept was generally well tolerated in clinical trials and there is little potential for systemic drug accumulation. Thus, intravitreal aflibercept is an effective and generally well tolerated agent that extends the options available for the treatment of macular oedema secondary to CRVO.
authors.affiliation: Adis, 41 Centorian Drive, Private Bag 65901 Mairangi Bay, North Shore, 0754, Auckland, New Zealand.
authors.forename: Lily P H
authors.initials: LP
authors.lastname: Yang
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D006801:Humans; D008269:Macular Edema / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D012170:Retinal Vein Occlusion / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor
references.citation: Br J Ophthalmol. 2013 Jul;97(7):917-23
references.pmid: 23686000
references.citation: Ophthalmologica. 2012;227 Suppl 1:2-10
references.pmid: 22517120
references.citation: Angiogenesis. 2012 Jun;15(2):171-85
references.pmid: 22302382
references.citation: Ophthalmology. 2014 Jul;121(7):1414-1420.e1
references.pmid: 24679444
references.citation: Ann Pharmacother. 2013 Jun;47(6):819-27
references.pmid: 23673531
references.citation: Drugs Aging. 2012 Oct;29(10):839-46
references.pmid: 23038609
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8
references.pmid: 12177445
references.citation: Ophthalmology. 2010 Feb;117(2):313-9.e1
references.pmid: 20022117
references.citation: Ophthalmology. 2012 May;119(5):1024-32
references.pmid: 22440275
references.citation: Br J Ophthalmol. 2008 May;92(5):667-8
references.pmid: 18356264
references.citation: Ophthalmology. 2012 Apr;119(4):802-9
references.pmid: 22301066
references.citation: Curr Eye Res. 2012 Dec;37(12):1171-4
references.pmid: 22991959
references.citation: Br J Ophthalmol. 2012 Sep;96(9):1157-8
references.pmid: 22446028
references.citation: Mayo Clin Proc. 2012 Jan;87(1):77-88
references.pmid: 22212972
references.citation: Drugs. 2012 Nov 12;72(16):2063-71
references.pmid: 23061805
references.citation: Ophthalmology. 2014 Jan;121(1):202-208
references.pmid: 24084497
references.citation: J Cell Physiol. 2003 May;195(2):241-8
references.pmid: 12652651
references.citation: Ophthalmology. 2011 Jun;118(6):1089-97
references.pmid: 21640257
references.citation: Ophthalmology. 2012 Dec;119(12):2537-48
references.pmid: 23084240
references.citation: Am J Ophthalmol. 2013 Mar;155(3):429-437.e7
references.pmid: 23218699
references.citation: Br J Ophthalmol. 2013 Mar;97(3):278-84
references.pmid: 23298885
references.citation: Retina. 2013 May;33(5):1056-61
references.pmid: 23266881